GARAGIOLA, ISABELLA MARIA
GARAGIOLA, ISABELLA MARIA
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Psychological and cognitive factors involved in decision‐making process of haemophilia carriers in reproductive choices
2023 I. Cutica, M. Mortarino, I. Garagiola, G. Pravettoni, F. Peyvandi
Knowledge and attitudes toward gene therapy of a cohort of Italian patients with hemophilia
2023 I. Cutica, M. Mortarino, I. Garagiola, G. Pravettoni, F. Peyvandi
Updates on Novel Non-Replacement Drugs for Hemophilia
2022 R. Gualtierotti, S. Pasca, A. Ciavarella, S. Arcudi, A. Giachi, I. Garagiola, C. Suffritti, S.M. Siboni, F. Peyvandi
Genetic variants at the chromosomal region 2q21.3 underlying inhibitor development in patients with severe haemophilia A
2022 S. Spena, A. Cairo, E. Pappalardo, M.M. Gorski, I. Garagiola, S. Hassan, R. Gualtierotti, F. Peyvandi
Development of a specific monoclonal antibody to detect male cells expressing the rps4y1 protein
2021 S. Spena, C. Cordiglieri, I. Garagiola, F. Peyvandi
Post-authorization pharmacovigilance for hemophilia in Europe and the USA: Independence and transparency are keys
2021 F. Peyvandi, I. Garagiola, P.M. Mannucci
Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A
2021 S. Hassan, R. Palla, C. Valsecchi, I. Garagiola, A. El-Beshlawy, M. Elalfy, V. Ramanan, P. Eshghi, M. Karimi, S.C. Gouw, P.M. Mannucci, F.R. Rosendaal, F. Peyvandi
Immune Responses to Plasma-Derived Versus Recombinant FVIII Products
2021 F. Peyvandi, S. Miri, I. Garagiola
The EHA research roadmap: Blood coagulation and hemostatic disorders
2021 S. Eichinger, P.E. Morange, M. Cattaneo, M. Fretigny, A. Rauch, A. van Hylckama Vlieg, D.-. Tregouet, W. Ruf, M. Levi, J.A. Paramo, T. van der Poll, P.A. Kyrle, I. Garagiola, F. Peyvandi
X Chromosome inactivation: a modifier of factor VIII and IX plasma levels and bleeding phenotype in Haemophilia carriers
2020 I. Garagiola, M. Mortarino, S.M. Siboni, M. Boscarino, M.E. Mancuso, M. Biganzoli, E. Santagostino, F. Peyvandi
Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects
2019 R. De Cristofaro, M. Sacco, S. Lancellotti, F. Berruti, I. Garagiola, C. Valsecchi, M. Basso, E. Di Stasio, F. Peyvandi
Real-life experience in switching to new extended half-life products at European haemophilia centres
2019 F. Peyvandi, I. Garagiola, M. Boscarino, A. Ryan, C. Hermans, M. Makris
Clinical advances in gene therapy updates on clinical trials of gene therapy in haemophilia
2019 F. Peyvandi, I. Garagiola
Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis
2018 F. Peyvandi, A. Cannavò, I. Garagiola, R. Palla, P.M. Mannucci, F.R. Rosendaal, A. El-Beshlawy, M. Elalfy, V. Ramanan, P. Eshghi, S. Hanagavadi, R. Varadarajan, M. Karimi, M.V. Manglani, C. Ross, G. Young, T. Seth, S. Apte, D.M. Nayak, E. Santagostino, M. Elisa Mancuso, A.C. Sandoval Gonzalez, J.N. Mahlangu, S. Bonanad Boix, M. Cerqueira, N.P. Ewing, C. Male, T. Owaidah, V. Soto Arellano, N.L. Kobrinsky, S. Majumdar, R. Perez Garrido, A. Sachdeva, M. Simpson, M. Thomas, E. Zanon, B. Antmen, K. Kavakl, M.J. Manco-Johnson, M. Martinez, E. Marzouka, M.G. Mazzucconi, D. Neme, A. Palomo Bravo, R. Paredes Aguilera, A. Prezotti, K. Schmitt, B.M. Wicklund, B. Zulfikar
Prediction of Factor VIII inhibitor development in the SIPPET cohort by mutational analysis and Factor VIII antigen measurement
2018 S. Spena, I. Garagiola, A. Cannavò, M. Mortarino, P.M. Mannucci, F.R. Rosendaal, F. Payvandi, A. El-Beshlawy, M. Elalfy, V. Ramanan, P. Eshghi, S. Hanagavadi, R. Varadarajan, M. Karimi, M.V. Manglani, C. Ross, G. Young, T. Seth, S. Apte, D.M. Nayak, E. Santagostino, M.E. Mancuso, A.C. Sandoval Gonzalez, J.N. Mahlangu, S. Bonanad Boix
Product type and other environmental risk factors for inhibitor development in severe hemophilia A
2018 F. Peyvandi, I. Garagiola
Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity
2018 I. Donadon, J.H. Mcvey, I. Garagiola, A. Branchini, M. Mortarino, F. Peyvandi, F. Bernardi, M. Pinotti
Risk factors for inhibitor development in severe hemophilia A
2018 I. Garagiola, R. Palla, F. Peyvandi
The Influence of F8 Mutation and Thrombophilic Genetic Markers on Bleeding Phenotype of Patients Affected with Severe Hemophilia A in the SIPPET Cohort
2017 A. Cannavò, S. Spena, R. Palla, I. Garagiola, A. El-Beshlawy, M. Elalfy, V. Ramanan, P. Eshghi, S. Hanagavadi, R. Varadarajan, M. Karimi, M.V. Manglani, C. Ross, G. Young, T. Seth, S. Apte, D.M. Nayak, E. Santagostino, M.E. Mancuso, A.C. Sandoval Gonzales, J.N. Mahlangu, S. Bonanad, M. Cerqueira, N.P. Ewing, C. Male, T. Owaidah, V. Soto Arellano, N.L. Kobrinsky, S. Majumdar, R. Perez Garrido, A. Sachdeva, M. Simpson, M. Thomas, E. Zanon, B. Antmen, K. Kavakli, M.J. Manco-Johnson, M. Martinez, E. Marzouka, M.G. Mazzucconi, D. Neme, A. Palomo, Bravo, R. Paredes Aguilera, A. Prezotti, K. Schmitt, B.M. Wicklund, B. Zulfikar, F.R. Rosendaal, P.M. Mannucci, F. Peyvandi
Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A : A SIPPET analysis
2017 F.R. Rosendaal, R. Palla, I. Garagiola, P.M. Mannucci, F. Peyvandi